Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic ...

Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

With skin cancer on the rise across the UK, Boots is expanding dermatology training for its in-store pharmacists. Matt Nixson tried out its mole-scanning service ...

Castle Biosciences and SciBase join forces to create a predictive test for atopic dermatitis flare-ups. Read more here.

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide ...